BIOLQ (Biolase) EBIT: $-13.59 Mil (TTM As of Sep. 2024)


BIOLQ Biolase Inc BIOLQ
16 GF Score
Price $0.00
View Full Analysis

What is Biolase EBIT?

Biolase BIOLQ -99.00% 16 EBIT is $-13.59 Mil as of Sep. 2024. GuruFocus rates BIOLQ with a GF Score™ of 16/100.

Biolase's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-0.81 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-13.59 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biolase's annualized ROC % for the quarter that ended in Sep. 2024 was -9.68%. Biolase's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -47.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biolase's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -89.08%.

Biolase  (OTCPK:BIOLQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biolase's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-2.78 * ( 1 - 0% )/( (27.474 + 29.955)/ 2 )
=-2.78/28.7145
=-9.68 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=30.641 - 12.249 - ( 5.272 - max(0, 31.176 - 22.094+5.272))
=27.474

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=27.241 - 8.717 - ( 3.444 - max(0, 30.859 - 19.428+3.444))
=29.955

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Biolase's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.244/( ( (5.364 + max(-0.175, 0)) + (4.627 + max(3.604, 0)) )/ 2 )
=-3.244/( ( 5.364 + 8.231 )/ 2 )
=-3.244/6.7975
=-47.72 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.842 + 10.904 + 1.076) - (12.249 + 2.132 + 2.616)
=-0.175

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.53 + 9.87 + 2.584) - (8.717 + 2.226 + 1.437)
=3.604

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biolase's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-13.585/15.250
=-89.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biolase EBIT Related Terms

Biolase EBIT Historical Data

* Premium members only.

The historical data trend for Biolase's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biolase EBIT Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.74 -14.34 -13.87 -25.78 -18.24

Biolase Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.98 -4.74 -5.84 -2.19 -0.81

BIOLQ vs OPGN, AFIB, ABT: EBIT Comparison

For the Medical Devices subindustry, Biolase's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolase EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biolase's EV-to-EBIT falls into.


BIOLQ
16GF Score
Biolase Inc BIOLQ
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biolase EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-13.59 Mil mean?
Biolase (BIOLQ) has a EBIT of $-13.59 Mil as of Sep. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biolase.
Is Biolase's EBIT too high?
Biolase's current EBIT is $-13.59 Mil. Overall, Biolase has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biolase's EBIT compare to OPGN and AFIB?
Biolase's EBIT of $-13.59 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Biolase. Biolase's current EBIT is $-13.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biolase stock overvalued right now?
Biolase (BIOLQ) has a current EBIT of $-13.59 Mil. The current EBIT is $-13.59 Mil. Biolase's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Biolase (BIOLQ), the current EBIT is $-13.59 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biolase Business Description

Address 27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
16GF Score

Get the complete analysis for BIOLQ

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price